These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9516853)

  • 41. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.
    Cohn SL; Salwen H; Quasney MW; Ikegaki N; Cowan JM; Herst CV; Kennett RH; Rosen ST; DiGiuseppe JA; Brodeur GM
    Oncogene; 1990 Dec; 5(12):1821-7. PubMed ID: 2284101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MYCN expression in human rhabdomyosarcoma cell lines and tumour samples.
    Toffolatti L; Frascella E; Ninfo V; Gambini C; Forni M; Carli M; Rosolen A
    J Pathol; 2002 Apr; 196(4):450-8. PubMed ID: 11920742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma.
    Svensson T; Rydén M; Schilling FH; Dominici C; Sehgal R; Ibáñez CF; Kogner P
    Eur J Cancer; 1997 Oct; 33(12):2058-63. PubMed ID: 9580079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MycN is a transcriptional regulator of livin in neuroblastoma.
    Dasgupta A; Peirce SK; Findley HW
    Oncol Rep; 2009 Oct; 22(4):831-5. PubMed ID: 19724862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells.
    Rellinger EJ; Craig BT; Alvarez AL; Dusek HL; Kim KW; Qiao J; Chung DH
    Surgery; 2017 Mar; 161(3):747-752. PubMed ID: 27919448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The MYCN protein of human neuroblastoma cells is phosphorylated by casein kinase II in the central region and at serine 367.
    Hamann U; Wenzel A; Frank R; Schwab M
    Oncogene; 1991 Oct; 6(10):1745-51. PubMed ID: 1923500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
    Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
    Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
    Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
    J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. N-myc and noncoding RNAs in neuroblastoma.
    Buechner J; Einvik C
    Mol Cancer Res; 2012 Oct; 10(10):1243-53. PubMed ID: 22936790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
    Kim R; Beck WT
    Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity.
    Peirce SK; Findley HW
    Oncol Rep; 2009 Dec; 22(6):1443-9. PubMed ID: 19885598
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line.
    Foley J; Cohn SL; Salwen HR; Chagnovich D; Cowan J; Mason KL; Parysek LM
    Cancer Res; 1991 Dec; 51(23 Pt 1):6338-45. PubMed ID: 1933896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
    Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
    J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
    Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
    Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
    Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
    J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells.
    Misawa A; Hosoi H; Arimoto A; Shikata T; Akioka S; Matsumura T; Houghton PJ; Sawada T
    Cancer Res; 2000 Jan; 60(1):64-9. PubMed ID: 10646854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MYCN-related suppression of functional CD44 expression enhances tumorigenic properties of human neuroblastoma cells.
    Gross N; Balmas Bourloud K; Brognara CB
    Exp Cell Res; 2000 Nov; 260(2):396-403. PubMed ID: 11035936
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced MYCN oncogene expression in human neuroblastoma cells results in increased susceptibility to growth inhibition by TNF alpha.
    Schweigerer L; Scheurich P; Fotsis T
    Biochem Biophys Res Commun; 1990 Aug; 170(3):1301-7. PubMed ID: 2202299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
    Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
    J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.